Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer
is associated with decreased overall survival. Trastuzumab, a humanized monoclonal …

Publisher Summary This chapter focuses on neuregulins (NRGs) that are the signaling
proteins that mediate cell–cell interactions in the nervous system, heart, breast, and other …

Dysregulation of human epidermal growth factor receptor (ErbB/HER) pathways by over-
expression or constitutive activation can promote tumor processes including angiogenesis …

As breast cancer survival is increased by the diagnosis of earlier-stage disease and
treatments improve, the side effects of cancer treatments, such as cardiotoxicity, remain …

Trastuzumab (Herceptin®) is a recombinant humanised IgG1 monoclonal antibody against
the human epidermal growth factor receptor 2 (HER2), used for metastatic breast cancer …

This review discusses 26 new anticancer drugs approved by the FDA in the past decade.
Based on their targets, these anticancer agents can be divided into three groups. First group …

Treatment of metastatic breast cancer with doxorubicin (Doxo) in combination with
trastuzumab, an antibody targeting the ErbB2 receptor, results in an increased incidence of …

Trastuzumab (Herceptin®) is a humanised monoclonal antibody used in the treatment of
breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2), which …

Signal transduction therapy for cancer targets signaling elements with key roles in cancer
cell survival and proliferation, but with more minor roles in the survival of healthy cells …

Neuregulins and their erbB receptors are essential for cardiac development and postulated
to be cardioprotective in the presence of injury in the postnatal heart. We tested the …